12,191 reports of this reaction
1.6% of all DUPILUMAB reports
#15 most reported adverse reaction
ACCIDENTAL EXPOSURE TO PRODUCT is the #15 most commonly reported adverse reaction for DUPILUMAB, manufactured by sanofi-aventis U.S. LLC. There are 12,191 FDA adverse event reports linking DUPILUMAB to ACCIDENTAL EXPOSURE TO PRODUCT. This represents approximately 1.6% of all 782,562 adverse event reports for this drug.
Patients taking DUPILUMAB who experience accidental exposure to product should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACCIDENTAL EXPOSURE TO PRODUCT is a less commonly reported adverse event for DUPILUMAB, but still significant enough to appear in the safety profile.
In addition to accidental exposure to product, the following adverse reactions have been reported for DUPILUMAB:
The following drugs have also been linked to accidental exposure to product in FDA adverse event reports:
ACCIDENTAL EXPOSURE TO PRODUCT has been reported as an adverse event in 12,191 FDA reports for DUPILUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACCIDENTAL EXPOSURE TO PRODUCT accounts for approximately 1.6% of all adverse event reports for DUPILUMAB, making it a notable side effect.
If you experience accidental exposure to product while taking DUPILUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.